Friday, June 3, 2022, Chicago, Illinois, 6:30 PM – 9:00 PM Central Time (7:30 PM – 10:00 PM Eastern Time)

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Lung Cancer

A CME Hybrid Symposium Held in Conjunction with the 2022 ASCO Annual Meeting

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Program Schedule — Central Time
6:00 PM – 6:30 PM — Registration and Dinner
6:30 PM – 9:00 PM — Educational Meeting

Meeting Room
Grand Ballroom (Level 2)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  
 
Faculty
Justin F Gainor, MD
Director, Center for Thoracic Cancers at Massachusetts General Hospital
Director of Targeted Immunotherapy in the
Henri and Belinda Termeer Center for Targeted Therapies
Associate Professor of Medicine, Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts

Corey J Langer, MD
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Luis Paz-Ares, MD, PhD
Chair of the Medical Oncology Department at the
Hospital Universitario 12 de Octubre
Associate Professor at the Universidad Complutense
Head of the Lung Cancer Unit at the National Oncology Research Center
Madrid, Spain


Heather Wakelee, MD
Professor of Medicine
Chief, Division of Oncology
Interim Medical Director, Stanford Cancer Center
Deputy Director, Stanford Cancer Institute
President, International Association for the Study of Lung Cancer (IASLC)
Stanford, California

Jared Weiss, MD
Professor of Medicine
UNC School of Medicine
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina

Helena Yu, MD
Medical Oncologist
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, New York

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Blueprint Medicines and Genentech, a member of the Roche Group, Daiichi Sankyo Inc, G1 Therapeutics Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Lilly, Regeneron Pharmaceuticals Inc and Sanofi, and Takeda Pharmaceuticals USA Inc.
Program Schedule — Central Time
6:00 PM – 6:30 PM — Registration and Dinner
6:30 PM – 9:00 PM — Educational Meeting

MODULE 1: Incorporation of Immunotherapeutic Strategies into the Management of Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) — Dr Wakelee

  • Design, eligibility criteria and key efficacy and safety findings from the Phase III IMpower010 trial evaluating atezolizumab versus best supportive care after adjuvant chemotherapy for completely resected NSCLC
  • Recent FDA approval of adjuvant atezolizumab for patients with Stage II to Stage IIIA NSCLC and PD-L1 expression ≥1%; optimal integration into practice
  • Recently presented data from the Phase III PEARLS/KEYNOTE-091 study of pembrolizumab as adjuvant therapy for Stage IB to IIIA NSCLC
  • Key findings from the Phase III CheckMate 816 trial evaluating nivolumab in combination with chemotherapy as neoadjuvant therapy for resectable NSCLC; recent FDA approval of neoadjuvant nivolumab and appropriate identification of candidates for this strategy
  • Long-term efficacy and safety findings, including 5-year overall survival data, from the Phase III PACIFIC trial evaluating consolidation durvalumab after chemoradiation therapy for unresectable Stage III NSCLC; patient selection for and practical implementation of consolidation durvalumab
  • Mechanisms of antitumor activity of oleclumab and monalizumab; efficacy and safety observed with durvalumab in combination with oleclumab or monalizumab in the randomized Phase II COAST study
  • Other data sets and ongoing clinical trials with immune checkpoint inhibitors for nonmetastatic NSCLC

MODULE 2: Contemporary Treatment for Localized and Metastatic NSCLC with EGFR Mutations — Dr Yu

  • Principal efficacy and safety findings, including rates of central nervous system (CNS) disease recurrence, from the Phase III ADAURA trial evaluating adjuvant osimertinib for localized NSCLC with an EGFR mutation
  • Recent FDA approval of adjuvant osimertinib; patient selection and optimal incorporation into clinical care
  • Optimal first-line treatment for patients with metastatic NSCLC and EGFR tumor mutations, including those with CNS metastases
  • Mechanisms of resistance to osimertinib; published findings with and ongoing evaluation of EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib and lazertinib combined with other agents for patients who experience disease progression on first-line osimertinib
  • Available data with and ongoing evaluation of the novel HER3-directed antibody-drug conjugate patritumab deruxtecan for metastatic EGFR TKI-resistant NSCLC
  • Efficacy and safety findings supporting the recent FDA accelerated approvals of amivantamab and mobocertinib for patients with metastatic NSCLC and EGFR exon 20 insertion mutations

MODULE 3: Research Advances Shaping the Current and Future Treatment of Metastatic NSCLC with ALK Rearrangements, ROS1 Rearrangements or RET Fusions — Dr Gainor

  • Key findings with novel ALK inhibitors (eg, alectinib, brigatinib, lorlatinib) as first-line therapy for patients with NSCLC with ALK rearrangements; clinical factors in the choice of up-front treatment
  • Indications for repeat biomarker testing for patients with progressive NSCLC with ALK rearrangements; selection of therapy for patients who experience disease progression on first-line ALK inhibition
  • Efficacy and safety results with entrectinib for NSCLC with ROS1 fusions; appropriate integration into clinical practice, including for patients with CNS involvement
  • Published data with and ongoing trials of other “next-generation” ROS1 inhibitors (eg, repotrectinib, lorlatinib)
  • Available safety and efficacy results with selpercatinib or pralsetinib for RET fusion-driven advanced NSCLC; current role in clinical practice
  • Design, eligibility and key endpoints of Phase III studies comparing first-line selpercatinib or pralsetinib to chemotherapy with or without pembrolizumab for patients with treatment-naïve NSCLC with RET fusions

MODULE 4: Targeting Alterations in MET, HER2, KRAS and Other Oncogenes in NSCLC — Dr Weiss

  • Key efficacy and safety findings with capmatinib or tepotinib for patients with NSCLC with MET exon 14 mutations
  • Current role and practical implementation of capmatinib and tepotinib in clinical practice
  • Principal efficacy and safety findings with sotorasib for patients with pretreated NSCLC with KRAS G12C mutations; recent FDA accelerated approval and optimal integration into practice
  • Recently presented results from the Phase II DESTINY-Lung01 study evaluating trastuzumab deruxtecan (T-DXd) for patients with NSCLC with HER2 mutations
  • FDA breakthrough therapy designation for T-DXd and potential nonresearch role for patients with NSCLC with HER2 mutations
  • Early data with and ongoing investigations of other novel agents and strategies (eg, telisotuzumab vedotin, datopotamab deruxtecan, seribantumab) for patients with actionable genomic abnormalities

MODULE 5: Current and Future Management of Metastatic NSCLC without a Targetable Tumor Mutation — Dr Langer

  • Clinical trial database supporting the FDA approvals of anti-PD-1/PD-L1 antibody monotherapy and combined chemoimmunotherapy for patients with newly diagnosed metastatic NSCLC
  • Available results with the use of cemiplimab in combination with platinum-based chemotherapy as up-front therapy for NSCLC
  • Long-term follow-up from Phase III trials (CheckMate 227, CheckMate 9LA) evaluating first-line nivolumab/ipilimumab with and without chemotherapy for metastatic NSCLC; optimal integration into practice
  • Principal findings from the Phase III POSEIDON trial evaluating first-line durvalumab or durvalumab and tremelimumab in combination with platinum-based chemotherapy
  • Biologic rationale for targeting TROP2 in lung cancer; mechanism of action of and available data with the TROP2-directed antibody-drug conjugate datopotamab deruxtecan for patients with progressive metastatic NSCLC
  • Other promising agents and strategies (eg, patritumab deruxtecan, plinabulin) for metastatic NSCLC without a targetable tumor mutation

MODULE 6: Current Treatment Paradigm for Small Cell Lung Cancer (SCLC) — Dr Paz-Ares

  • Long-term efficacy and safety findings from the Phase III CASPIAN and IMpower133 studies of durvalumab and atezolizumab, respectively, in combination with chemotherapy as first-line treatment for extensive-stage SCLC; factors in selecting a regimen
  • Major efficacy and safety findings from key studies (eg, the pivotal Phase II basket trial, ATLANTIS) of lurbinectedin for patients with SCLC who experienced disease progression after prior chemotherapy
  • Current clinical role of lurbinectedin for progressive SCLC; ongoing efforts to combine lurbinectedin with other systemic therapies
  • Efficacy and safety results from randomized studies evaluating trilaciclib as a means to preserve bone marrow function during chemotherapy in patients with extensive-stage SCLC; recent FDA approval and optimal incorporation of trilaciclib into routine practice
  • Other novel agents and strategies under investigation for patients with extensive- or limited-stage SCLC

Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Evaluate available data documenting the efficacy and safety of anti-PD-1/PD-L1 antibody-based approaches as neoadjuvant or adjuvant therapy for patients with nonmetastatic non-small cell lung cancer (NSCLC).
  • Appraise the FDA approval of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III NSCLC, and appropriately integrate this strategy into clinical practice.
  • Acknowledge the FDA approval of adjuvant EGFR tyrosine kinase inhibitor (TKI) therapy for localized NSCLC with EGFR mutations, and identify patients for whom this novel approach would be warranted.
  • Review published research data documenting the safety and efficacy of EGFR TKIs alone or with other systemic therapies for metastatic NSCLC with an EGFR tumor mutation, and appropriately apply this information in patient care.
  • Assess the efficacy and safety of commercially available ALK inhibitors for metastatic NSCLC with an ALK rearrangement, and apply this understanding to the selection and sequencing of these drugs.
  • Recall other oncogenic pathways mediating the pathogenesis of tumors in unique patient subsets (ie, ROS1, RET, MET, HER2, KRAS), and recall published data with commercially available and experimental agents exploiting these targets.
  • Review recent therapeutic advances related to the use of anti-PD-1/PD-L1 antibodies as monotherapy or in combination for metastatic NSCLC, and discern how these approaches can be optimally employed in the management of this disease.
  • Appreciate available clinical trial findings informing the use of immune checkpoint inhibitors in combination with platinum-based chemotherapy for previously untreated extensive-stage small cell lung cancer (SCLC).
  • Design an optimal approach to the clinical care of patients with progressive SCLC, considering prior therapeutic exposure, symptomatology and other factors.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYDr Wakelee has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr GainorConsulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Gilead Sciences Inc, Helsinn Healthcare SA, Incyte Corporation, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Oncorus, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Adaptimmune, ALX Oncology, Array BioPharma Inc, a subsidiary of Pfizer Inc, Blueprint Medicines, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Jounce Therapeutics, Merck, Moderna, Novartis, Scholar Rock, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company; Employment (Immediate Family Member): Ironwood Pharmaceuticals. Dr LangerAdvisory Committee: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, GlaxoSmithKline, Guardant Health, Lilly, Merck, Pfizer Inc, Takeda Pharmaceuticals USA Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Lilly, Merck, Novartis, Novocure Inc, Regeneron Pharmaceuticals Inc; Contracted Research: Advantagene Inc, Amgen Inc, Lilly, Merck, Takeda Pharmaceuticals USA Inc, Trizell; Data and Safety Monitoring Board/Committee: US Department of Veterans Affairs, OncocyteRx. Dr Paz-AresBoard: GENOMICA SAU; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp, Pfizer Inc; Speakers Bureau: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, GlaxoSmithKline, Janssen Biotech Inc, Lilly, Merck, Merck Sharp & Dohme Corp, Mirati Therapeutics, Novartis, Pfizer Inc, PharmaMar, Roche Laboratories Inc, Sanofi Genzyme, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc. Dr WeissConsulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Azitra, Boehringer Ingelheim Pharmaceuticals Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Jazz Pharmaceuticals Inc, Lilly, Nanobiotix, Pfizer Inc, Regeneron Pharmaceuticals Inc, Saatchi & Saatchi Wellness, Sumitomo Dainippon Pharma Oncology Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, G1 Therapeutics Inc, Inspirna, Merck; Data and Safety Monitoring Board/Committee: BeiGene Ltd, EMD Serono Inc, Jounce Therapeutics; Ownership Interest: Achilles Therapeutics, Lyell, Nuvalent, Vesselon (warrants). Dr YuConsulting Agreements: AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Blueprint Medicines, C4 Therapeutics, Cullinan Oncology, Daiichi Sankyo Inc, Janssen Biotech Inc; Research Funding (to Institution): AstraZeneca Pharmaceuticals LP, Cullinan Oncology, Daiichi Sankyo Inc, Erasca, Janssen Biotech Inc, Pfizer Inc, Novartis.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Blueprint Medicines and Genentech, a member of the Roche Group, Daiichi Sankyo Inc, G1 Therapeutics Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Lilly, Regeneron Pharmaceuticals Inc and Sanofi, and Takeda Pharmaceuticals USA Inc.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Meeting Room:
Grand Ballroom (Level 2)

Directions:
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

 
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of lung cancer.

There is no fee to participate in this program or live webcast of this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.

Registration for in-person meeting

In order to attend this in-person event, please register here.

Registration for event »
 
Registration for live webcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.